MHLW (Japan) approves Darvias injection to treat peripheral T cell lymphoma.-Solasia Pharma and Nippon Kayaku.
Solasia Pharma K.K officially announced that an organoarsenic drug “Darvias Injection 135mg” (SP-02, hereinafter Darvias) has been approved for relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare (MHLW). Solasia filed an NDA with the MHLW in Japan in June 2021.
In October 2021, Nippon Kayaku Co., Ltd. (TSE: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) secured a license agreement with Darvias for marketing rights in Japan.
Related news and insights
Palisade Bio, Inc. announced the first patient has been dosed in its Phase III study evaluating LB 1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.
bluebird bio, Inc. announced the FDA has approved Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions.
Edwards Lifesciences Corporation announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR).